# US 2017/0246130 A1 · 4-hydroxybenzohydarzide-a new class of angiogenic enzyme thymidine phosphorylase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0246130 A1
- Document ID: US20170246130A1
- Status: Published application
- Kind: A1
- Application number: 15/053,887
- Filed: 2016-02-25
- Published: 2017-08-31
- Earliest claimed: 2016-02-25
- Inventors: Muhammad Iqbal Choudhary; Sumaira Javaid; Khalid M. Khan; Syed Muhammad Saad; Atia-tul Wahab; Atta-ur- Rahman
- Web page: https://patentgrep.com/patent/US20170246130A1

## CPC

- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to anti-thymidine phosphorylase compounds. These compounds are derivatives of 4-hydroxybenzohydarzide or generally Schiff bases of hydrazones. The invention evaluates a series of Schiff bases of hydrazones against thymidine phosphorylase, and identified significant inhibitors of thymidine phosphorylase enzyme during in vitro studies.

## Claims

### Claim 1

A method for treating cancer in humans in need of treatment, administering a suitable dose of an inhibitor of thymidine phosphorylase enzymes selected from a group 4-hydroxybenzohydrazide derivatives consisting of:
4-Hydroxy-N′-[(E)-(2-hydroxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(3-hydroxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(4-hydroxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(2,3-dihydroxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(3,4-dihydroxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(2,4,5-trihydroxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(2-methoxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(4-methoxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(3,4-dimethoxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(4-chlorophenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(3-chlorophenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(4-bromophenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(2,4-dichlorophenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(2-methylphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(2-hydroxy-3-methoxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(2-hydroxy-5-methoxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(3-ethoxy-2-hydroxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-(3,5-dibromo-2-hydroxyphenyl)methylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-1-(2,6-dihydroxyphenyl)ethylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-1-(2,5-dihydroxyphenyl)ethylidene]benzohydrazide;
4-Hydroxy-N′-[(E)-1-(2-hydroxy-3-methoxyphenyl)ethylidene]benzohydrazide; and
4-Hydroxy-N′-[(E)-1-(2,5-dihydroxyphenyl)propylidene]benzohydrazide
combined with suitable inert pharmaceutical ingredients.

### Claim at position 2

2-3. (canceled)
